Bullous pemphigoid associated with use of dipeptidyl peptidase-4 inhibitor

Bullous pemphigoid is an autoimmune blistering disease, characterized by severe pruritis, tense bullae and edematous erythema. Dipeptidyl peptidase-4 inhibitors are commonly used to treat diabetes, and are associated with development of noninflammatory bullous pemphigoid, with an incidence of 0.42 p...

Full description

Saved in:
Bibliographic Details
Published in:Canadian Medical Association journal (CMAJ) 2022-05, Vol.194 (20), p.E705-E705
Main Authors: Kano, Yasuhiro, Kato, Miyuki
Format: Article
Language:English
Subjects:
Autoimmune diseases
Bullous pemphigoid
Case reports
Case studies
Causes of
Complications and side effects
Diabetes
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Dipeptidyl-Peptidase IV Inhibitors - adverse effects
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
Enzyme inhibitors
Erythema
Health risks
Humans
Hypoglycemic Agents
Inhibitor drugs
Patients
Pemphigoid, Bullous - chemically induced
Pemphigoid, Bullous - complications
Practice
Side effects
Skin diseases
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bullous pemphigoid is an autoimmune blistering disease, characterized by severe pruritis, tense bullae and edematous erythema. Dipeptidyl peptidase-4 inhibitors are commonly used to treat diabetes, and are associated with development of noninflammatory bullous pemphigoid, with an incidence of 0.42 per 1000 person- years. Reported risk factors for development include male sex, white race and use of vildagliptin or linagliptin. Bullous pemphigoid usually begins several months to years after the initiation of a DPP-4 inhibitor. Here, Kano and Kato discuss the case of an 86-year-old man with bullous pemphigoid.
ISSN:0820-3946
1488-2329
DOI:10.1503/cmaj.211933